www.fdanews.com/articles/211230-modernas-influenza-mrna-vaccine-candidate-displays-mixed-results
Moderna’s Influenza mRNA Vaccine Candidate Displays Mixed Results
February 21, 2023
Moderna’s investigational messenger RNA (mRNA) vaccine for influenza — mRNA-1010 — has shown mixed efficacy in interim results from a phase 3 clinical trial.
The vaccine candidate targets four influenza strains, including influenza A/H1N1, A/H3N2, influenza B/Yamagata- and B/Victoria. The interim data showed strong efficacy against the A/H3N2 and A/H1N1 strains but less against the two others.
The trial included more than 6,000 adults in Argentina, Australia, Colombia, Panama and the Philippines during the Southern Hemisphere influenza season.